How Investors Are Reacting To Healthpeak Properties (DOC) Being Dropped From the FTSE All-World Index

• Healthpeak Properties, Inc. (NYSE:DOC) was recently removed from the FTSE All-World Index, an international equity benchmark followed by many institutional investors.
• This index exclusion highlights the potential for broad portfolio adjustments by funds that track the index and may influence trading activity for the stock.
• With this change in global index inclusion, we will explore how Healthpeak Properties' investment narrative may be affected by reduced passive fund demand.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Healthpeak Properties Investment Narrative Recap

To be a shareholder in Healthpeak Properties, you need conviction in the long-term growth of high-acuity outpatient and life science real estate, driven by demographic trends and evolving healthcare delivery. The recent removal from the FTSE All-World Index is unlikely to materially affect the most significant short-term catalyst, a potential demand uplift in outpatient medical centers, or change the leading current risk, which remains credit and capital market challenges among biotech and healthcare tenants. Among recent announcements, the $500 million senior notes offering on August 14, 2025 stands out, providing liquidity that may help manage capital expenses and refinance near-term obligations. While this supports financial flexibility, it only partly addresses ongoing credit risks surrounding parts of the tenant base, meaning the underlying risk profile is unchanged. Conversely, investors should be aware that persistent credit strain in Healthpeak's biotech tenant base could rapidly compound if...

Read the full narrative on Healthpeak Properties (it's free!)

Healthpeak Properties' outlook projects $3.1 billion in revenue and $198.8 million in earnings by 2028. This is based on an assumed 3.0% annual revenue growth and a $34.8 million increase in earnings from the current $164.0 million.

Uncover how Healthpeak Properties' forecasts yield a $21.38 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Five Simply Wall St Community fair value estimates for Healthpeak range from US$14.63 to US$31.73 per share. While views differ greatly, persistent credit and capital-raising issues for tenants could weigh on future earnings, so it pays to consider a range of opinions.

Explore 5 other fair value estimates on Healthpeak Properties - why the stock might be worth as much as 68% more than the current price!

Build Your Own Healthpeak Properties Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Healthpeak Properties research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Healthpeak Properties research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Healthpeak Properties' overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com